<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144217</url>
  </required_header>
  <id_info>
    <org_study_id>TMP-2501-2019-2</org_study_id>
    <nct_id>NCT05144217</nct_id>
  </id_info>
  <brief_title>Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo</brief_title>
  <acronym>SILVER</acronym>
  <official_title>Impact of Different Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo in a Prospective Controlled Dose Finding Phase IIb Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Frank Behrens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bionorica SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraunhofer Institute for Molecular Biology and Applied Ecology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical study silymarin will be administered in different dosages and compared to&#xD;
      placebo in order to address if the liver protecting features of silymarin, measured by&#xD;
      changes of liver enzyme concentration, can be improved in patients with drug-induced elevated&#xD;
      liver enzymes or drug-induced hepatocellular liver injury with higher systemic&#xD;
      bioavailabilities due to administration of higher oral dosages or administration of higher&#xD;
      administration frequency over a 35-day treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical routine care, drug-induced elevation of liver enzymes occurs often in parallel to&#xD;
      new treatment initiation, possibly leading to interruption of treatment strategies if liver&#xD;
      enzyme elevation does not normalize within 2 to 4 weeks.&#xD;
&#xD;
      Liver injury from medications usually occurs within 6 months of drug initiation and typically&#xD;
      within the first 1-4 weeks1. In general, drug-induced liver injury (DILI) is related to the&#xD;
      class of drug, the quantity of drug consumed, the patient's age and sex, and such concurrent&#xD;
      factors as diabetes mellitus, excessive alcohol intake, e.g. high caloric diet, which can&#xD;
      lead to NAFLD/steatosis, or the use of other medications. Drugs administered in higher doses&#xD;
      are more likely to cause liver injury, especially drugs that require extensive hepatic&#xD;
      metabolism1. Different forms of drug-induced elevation of liver enzymes can be differentiated&#xD;
      according to localisation of the injury: hepatocellular or cholestatic liver injury or a&#xD;
      mixture of both.Besides methotrexate and isozid, other medications have been reported to&#xD;
      induce hepatocellular liver injury: acarbose, allopurinol, amiodarone, baclofen, bupropion,&#xD;
      fluoxetine, ketoconazole, lisinopril, losartan, non-steroidal anti-inflammatory drugs&#xD;
      (NSAIDs), omeprazole, paracetamol, paroxetine, pyrazinamide, rifampicin, risperidone,&#xD;
      sertraline, statins, tetracyclines, trazodone, and valproic acid. Silymarin containing oral&#xD;
      preparations are widely used for their liver protecting characteristics. The milk thistle&#xD;
      ingredient silibinin is registered for continuous intravenous administration in the case of&#xD;
      acute liver intoxications such as consumption of amanita mushrooms. Although its mode of&#xD;
      action is still not clear, the clinical therapeutic benefits in patients with liver diseases&#xD;
      are documented.&#xD;
&#xD;
      Pharmacokinetics of silymarin after oral administration are well understood. Due to its poor&#xD;
      solubility in aqueous media, absorption from the intestinal tract is generally limited.&#xD;
      Silymarin's systemic bioavailability of marketed products is therefore rather low, also&#xD;
      because of predominant first pass biliary elimination. Exact PK/PD relations of the compound&#xD;
      have not been assessed so far.&#xD;
&#xD;
      Hence, in this clinical study silymarin will be administered in different dosages and&#xD;
      compared to placebo in order to address the following question: Can liver protecting features&#xD;
      of silymarin, measured by changes of liver enzyme concentration, be improved in patients with&#xD;
      drug-induced elevated liver enzymes or drug-induced hepatocellular liver injury with higher&#xD;
      systemic bioavailabilities due to administration of higher oral dosages or administration of&#xD;
      higher administration frequency over a 35-day treatment period?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective placebo-controlled dose-finding study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>study medication and placebo are provided in identical blister</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood ALT (Alanine-Aminotransferase) in IU/L</measure>
    <time_frame>at day 35</time_frame>
    <description>Change in blood ALT in IU/Lin all treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme blood parameter AST (Aspartate-Aminotransferase)</measure>
    <time_frame>Baseline (prior treatment)</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme blood parameter AST</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme blood parameter AST</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme blood parameters: AST</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver enzyme blood parameter AST</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AST</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter AST in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Baseline</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter ALT</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter ALT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Baseline</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter GGT (Gamma-Glutamyl-Transferase)</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter GGT in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Baseline</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/Lin all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/L in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter AP (Alkaline phosphatase )</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter AP in IU/L in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Baseline</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter bilirubin</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter bilirubin in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>baseline</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter INR (International Normalized Ratio)</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter INR in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>baseline</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Liver enzyme blood parameter Quick value</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of Liver enzyme blood parameter Quick value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>baseline</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>Day 7</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>Day 14</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>Day 21</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>Day 28</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ALT/AP ratio</measure>
    <time_frame>Day 35</time_frame>
    <description>Change of ALT/AP ratio in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis LDL</measure>
    <time_frame>Day 7</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis LDL</measure>
    <time_frame>Day 14</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis LDL</measure>
    <time_frame>Day 21</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis LDL</measure>
    <time_frame>Day 28</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis LDL</measure>
    <time_frame>Day 35</time_frame>
    <description>LDL (Low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>baseline</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day 7</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day 14</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day 21</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day 28</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day 35</time_frame>
    <description>HDL (High Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis</measure>
    <time_frame>Day baseline</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis VLDL</measure>
    <time_frame>Day 7</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis VLDL</measure>
    <time_frame>Day 14</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis VLDL</measure>
    <time_frame>Day 21</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis VLDL</measure>
    <time_frame>Day 28</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis VLDL</measure>
    <time_frame>Day 35</time_frame>
    <description>VLDL (very low Density Lipoproteins) in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>baseline</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>Day 7</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>Day 14</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>Day 21</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>Day 28</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis triglycerides</measure>
    <time_frame>Day 35</time_frame>
    <description>triglycerides in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>baseline</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>Day 7</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>Day 14</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>Day 21</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>Day 28</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids analysis total cholesterol</measure>
    <time_frame>Day 35</time_frame>
    <description>total cholesterol in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bloodparameter assessment</measure>
    <time_frame>baseline</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bloodparameter assessment</measure>
    <time_frame>Day 7</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameter assessment</measure>
    <time_frame>Day 14</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameter assessment</measure>
    <time_frame>Day 21</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameter assessment</measure>
    <time_frame>Day 28</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood parameter assessment</measure>
    <time_frame>Day 35</time_frame>
    <description>fasting glucose value in all treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with normalization in liver enzyme blood parameters</measure>
    <time_frame>Day 35</time_frame>
    <description>normalisation of liver enzyme blood parameters such as AST (&lt; 40 IU/L), ALT (&lt; 40 IU/L), GGT, AP, bilirubin, INR, Quick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>Base line</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>day 7</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>day 14</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>day 21</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>day 28</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma silymarin dose concentration</measure>
    <time_frame>day 35</time_frame>
    <description>concentration of silymarin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value</measure>
    <time_frame>baseline</time_frame>
    <description>measurement of Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value</measure>
    <time_frame>day 14</time_frame>
    <description>measurement of Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan value</measure>
    <time_frame>day 35</time_frame>
    <description>measurement of Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis score</measure>
    <time_frame>baseline</time_frame>
    <description>score F0 to F4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis score</measure>
    <time_frame>Day 14</time_frame>
    <description>score F0 to F4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis score</measure>
    <time_frame>Day 35</time_frame>
    <description>score F0 to F4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAP score</measure>
    <time_frame>baseline</time_frame>
    <description>score measured in dB/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAP score</measure>
    <time_frame>day 14</time_frame>
    <description>score measured in dB/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAP score</measure>
    <time_frame>day 35</time_frame>
    <description>score measured in dB/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>baseline</time_frame>
    <description>index measured in weight and height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Silymarin concentration in blood plasma in pharmakokinetic substudy - AUC</measure>
    <time_frame>baseline</time_frame>
    <description>assessement of area under the curve (AUC),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Silymarin concentration in blood plasma in pharmakokinetic substudy - tmax</measure>
    <time_frame>baseline</time_frame>
    <description>assessement of time to maximal concentration (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Silymarin concentration in blood plasma in pharmakokinetic substudy - Cmax</measure>
    <time_frame>baseline</time_frame>
    <description>assessement of maximal concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Baseline</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Day 7</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Day 14</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Day 21</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Day 28</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>Day 35</time_frame>
    <description>measured by patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>baseline</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>Day 7</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>Day 14</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>Day 21</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>Day 28</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life measurements</measure>
    <time_frame>Day 35</time_frame>
    <description>measured by short form survey (SF36) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Drug-induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral administration of 2x 140 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 capsule twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral administration of 3x 280 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 capsules three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral administration of 1x 1120 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 capsules once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule per day of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2x 140 mg per day</intervention_name>
    <description>2 capsule per day of silimarit</description>
    <arm_group_label>oral administration of 2x 140 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3x 280 mg per day</intervention_name>
    <description>3 capsule per day of silimarit</description>
    <arm_group_label>oral administration of 3x 280 mg per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1x 1120 mg</intervention_name>
    <description>8 capsule per day of silimarit</description>
    <arm_group_label>oral administration of 1x 1120 mg per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Evidence of hepatocellular drug-induced injury due to treatment*&#xD;
&#xD;
          -  ALT/AP ratio ≥ 5 ((ALT level/ALT upper limit of normal (ULN))/(AP level/AP ULN)) OR&#xD;
             Evidence of drug-induced elevation of liver-enzymes&#xD;
&#xD;
          -  ALT &gt; 40 U/L and ≤ 2 x ULN&#xD;
&#xD;
          -  ALT (&gt; 40 U/L) ≥ 2 weeks and ≤ 3 months 3. Documentation (within the last 4 weeks&#xD;
             before screening) of exclusion of liver tissue damage using either ultrasonography of&#xD;
             the liver or Fibroscan with results ≤ 7 kPa (fibrosis score of F0 to F1) 4. BMI ≥ 18&#xD;
             and ≤ 30 5. Liver enzyme elevation inducing medication stable for ≥ 8 weeks before&#xD;
             screening in the discretion of the treating physician 6. Written informed consent,&#xD;
             after having been informed about potential benefit and potential risks of the clinical&#xD;
             trial 7. Willing and capable to understand informed consent and follow the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of silymarin within the last 6 months&#xD;
&#xD;
          2. Current intake and intake within the last 4 weeks of drugs that have been shown to&#xD;
             induce cholestatic or mixed hepatocellular/cholestatic liver injury (inducing&#xD;
             cholestatic liver injury: amoxicilline and clavulanic acid, anabolic steroids,&#xD;
             chlorpromazine, clopidogrel, erythromycin, irbesartan, mirtazapine, estrogen,&#xD;
             terbinafine; inducing mixed liver injury: amitriptyline, azathioprine, captopril,&#xD;
             carbamazepine, clindamycin, co-trimoxazole, cyproheptadine, enalapril, flutamide,&#xD;
             nitrofurantoin, phenobarbital, phenytoin, sulphonamide, trazodone, verapamil)&#xD;
&#xD;
          3. Patients with chronic liver disease, existing fibrosis or cirrhosis&#xD;
&#xD;
          4. Patients with acute viral hepatitis, autoimmune hepatitis or immune-mediated hepatitis&#xD;
             (e.g., with immune checkpoint inhibitor treatment), acute Budd-Chiari syndrome, Wilson&#xD;
             disease, and ischemic liver injury&#xD;
&#xD;
          5. Cholestatic or mixed hepatocellular/mixed liver injury&#xD;
&#xD;
          6. Patients with diabetes types 1 or 2&#xD;
&#xD;
          7. Any malignancy within the past 5 years&#xD;
&#xD;
          8. Patients with chronic intestinal diseases (e.g., ulcerative colitis) and intestinal&#xD;
             barrier dysfunction in the discretion of the treating physician (e.g., patient can be&#xD;
             included if disease is judged as stable by the treating physician with no likely&#xD;
             interference with the study outcomes and the safety of the patient)&#xD;
&#xD;
          9. Evidence of significant uncontrolled concomitant diseases or serious and/or&#xD;
             uncontrolled diseases that are likely to interfere with the evaluation of the&#xD;
             patient's safety and of the study outcome&#xD;
&#xD;
         10. History of relevant central nervous system (CNS) and/or psychiatric disorders and/or&#xD;
             currently treated CNS and/or psychiatric disorders&#xD;
&#xD;
         11. Known allergic reactions to the active ingredients used or to constituents of the&#xD;
             pharmaceutical preparations, e.g. milk thistle, soy oil, peanut (according to Summary&#xD;
             of Product Characteristics (SmPc))&#xD;
&#xD;
         12. Contraindications to use the investigational medicinal product (IMP), e.g. hereditary&#xD;
             galactose intolerance, genetic lactase deficiency or glucose-galactose malabsorption&#xD;
             (according to SmPC)&#xD;
&#xD;
         13. Subjects with severe or moderate allergies or multiple drug allergies unless it is&#xD;
             judged as not relevant for the clinical trial by the investigator&#xD;
&#xD;
         14. Laboratory values other than target parameters out of normal range unless the&#xD;
             deviation from normal is judged as not relevant for the clinical trial by the&#xD;
             investigator&#xD;
&#xD;
         15. Positive anti-HIV-test, antiHBs- or anti-HCV-test at Screening&#xD;
&#xD;
         16. History of or current drug or alcohol dependence&#xD;
&#xD;
         17. Subjects with a positive drug test at screening (incl. alcohol)&#xD;
&#xD;
         18. Regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol for male or ≥ 20&#xD;
             g pure ethanol for female per day&#xD;
&#xD;
         19. Participation in a clinical trial during the last two months prior to individual&#xD;
             enrolment of the subject or current participation&#xD;
&#xD;
         20. Use of drugs during the last two weeks prior Baseline that can affect absorption (e.g.&#xD;
             laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists)&#xD;
&#xD;
         21. Subjects who are unable to understand the written and verbal instructions, in&#xD;
             particular regarding the risks and inconveniences they will be exposed to during their&#xD;
             participation in the clinical trial&#xD;
&#xD;
         22. Subjects who do not agree to apply adequate contraceptive methods as defined in Note&#xD;
             for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials&#xD;
             for Pharmaceuticals (CPMP/ICH/286/95, modification), November 2000&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Schaefer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fraunhofer ITMP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universtity Hospital - clinic for dermatology, venerology and allergology</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessia</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessia</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fraunhofer Institute for Molecular Biology and Applied Ecology</investigator_affiliation>
    <investigator_full_name>Dr. Frank Behrens</investigator_full_name>
    <investigator_title>Sponsor representative</investigator_title>
  </responsible_party>
  <keyword>silymarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

